Thymosin beta-4 research: studies, doses and safety

A peptide studied for eye conditions and skin wounds; tendon-repair injections lack controlled human evidence.

Also called: Tβ4, TB4, TB-4, Timbetasin, Timbetasin acetate, RGN-259, RGN-137, RGN-352, NL005, a recombinant Tβ4-related product.

Healing and repair peptides · Full-length actin-binding peptide; related recombinant trial formulations.

Large dry-eye trials and ulcer results combining gel strengths showed no clear benefit. No controlled human trial supports routine tendon-repair injections.

Key studies

  • Synthetic Tβ4: IV dose finding: Short-term IV tolerability does not establish a subcutaneous recovery dose. (source)
  • NL005: single IV doses: Early IV safety and PK only; not an efficacy or subcutaneous-dose trial. (source)
  • NL005: 10 daily IV doses: Early IV safety and PK only; not an efficacy or subcutaneous-dose trial. (source)
  • Corneal defects: four compassionate-use cases: Uncontrolled corneal observations; likely overlap with the nine-case report. (source)
  • Corneal defects: nine compassionate-use cases: Small uncontrolled series with improvement in some corneal defects. (source)
  • Severe dry eye: six doses daily: Promising but extremely small; eyes are not independent participants. (source)

Related to Thymosin beta-4

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.